Japanese Encephalitis - Pipeline Review, H2 2016

Date: October 12, 2016
Pages: 49
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: J92F84196C8EN
Leaflet:

Download PDF Leaflet

Japanese Encephalitis - Pipeline Review, H2 2016
Japanese Encephalitis - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Japanese Encephalitis - Pipeline Review, H2 2016, provides an overview of the Japanese Encephalitis (Central Nervous System) pipeline landscape.

Japanese encephalitis is a viral disease that infects animals and humans. It is caused by a flavivirus that affects the membranes around the brain. It is transmitted by mosquitoes. Symptoms include fever, headache, muscle pain, diarrhea, seizures, muscle weakness and paralysis. Treatment targets relief of symptoms like pain relievers and anticonvulsants.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Japanese Encephalitis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Japanese Encephalitis (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Japanese Encephalitis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Japanese Encephalitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical, Discovery and Unknown stages are 1, 1, 5, 3 and 1 respectively for Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively for Japanese Encephalitis.

Japanese Encephalitis (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Japanese Encephalitis (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Japanese Encephalitis (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Japanese Encephalitis (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Japanese Encephalitis (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Japanese Encephalitis (Central Nervous System)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Japanese Encephalitis (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Japanese Encephalitis (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Japanese Encephalitis Overview
Therapeutics Development
Pipeline Products for Japanese Encephalitis - Overview
Pipeline Products for Japanese Encephalitis - Comparative Analysis
Japanese Encephalitis - Therapeutics under Development by Companies
Japanese Encephalitis - Therapeutics under Investigation by Universities/Institutes
Japanese Encephalitis - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Japanese Encephalitis - Products under Development by Companies
Japanese Encephalitis - Products under Investigation by Universities/Institutes
Japanese Encephalitis - Companies Involved in Therapeutics Development
Ennaid Therapeutics, LLC
Indian Immunologicals Limited
Kineta, Inc.
Livzon Pharmaceutical Group Inc.
Panacea Biotec Limited
Vaxine Pty Ltd
Zydus Cadila Healthcare Limited
Japanese Encephalitis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
FDX-000 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Japanese encephalitis vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Japanese encephalitis vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Japanese encephalitis vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Japanese encephalitis vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Japanese encephalitis vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Japanese encephalitis vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Japanese encephalitis vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Japanese encephalitis vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Japanese encephalitis vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KIN-1400 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit NS5 for Japanese Encephalitis and Viral Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides for Japanese Encephalitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Japanese Encephalitis - Dormant Projects
Japanese Encephalitis - Discontinued Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 49

LIST OF TABLES

Number of Products under Development for Japanese Encephalitis, H2 2016
Number of Products under Development for Japanese Encephalitis - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Japanese Encephalitis - Pipeline by Ennaid Therapeutics, LLC, H2 2016
Japanese Encephalitis - Pipeline by Indian Immunologicals Limited, H2 2016
Japanese Encephalitis - Pipeline by Kineta, Inc., H2 2016
Japanese Encephalitis - Pipeline by Livzon Pharmaceutical Group Inc., H2 2016
Japanese Encephalitis - Pipeline by Panacea Biotec Limited, H2 2016
Japanese Encephalitis - Pipeline by Vaxine Pty Ltd, H2 2016
Japanese Encephalitis - Pipeline by Zydus Cadila Healthcare Limited, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Japanese Encephalitis - Dormant Projects, H2 2016
Japanese Encephalitis - Discontinued Products, H2 2016 47

LIST OF FIGURES

Number of Products under Development for Japanese Encephalitis, H2 2016
Number of Products under Development for Japanese Encephalitis - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


Japanese Encephalitis - Pipeline Review, H1 2016 US$ 1,700.00 Apr, 2016 · 43 pages
Eastern Equine Encephalitis - Pipeline Review, H2 2015 US$ 1,600.00 Aug, 2015 · 31 pages
Western Equine Encephalitis - Pipeline Review, H2 2015 US$ 1,600.00 Sep, 2015 · 37 pages
Eastern Equine Encephalitis - Pipeline Review, H1 2015 US$ 1,600.00 Jan, 2015 · 30 pages
Western Equine Encephalitis - Pipeline Review, H1 2015 US$ 1,600.00 Feb, 2015 · 27 pages

Ask Your Question

Japanese Encephalitis - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: